Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 4361 results
Turing advances several experimental compounds into pre-clinical development
Turing Pharmaceuticals has advanced several experimental compounds into pre-clinical development.
Drug Research > Drug Discovery & Development > News
Allergan to acquire Tobira Therapeutics in $1.7bn deal
By PBR Staff Writer
Allergan has agreed to acquire clinical-stage biopharmaceutical firm Tobira Therapeutics in a deal worth about $1.7bn.
Drug Research > Drug Discovery & Development > News
Alnylam opens new development and commercial hub in Maidenhead, UK
RNAi therapeutics firm Alnylam Pharmaceuticals has opened a new development and commercial hub in Maidenhead, UK.
Drug Research > Drug Discovery & Development > News
Aerie Pharmaceuticals raises $125m in public offerings
Aerie Pharmaceuticals announced the pricing of a registered underwritten public offering of $75m of shares of its common stock at a price to the public of $29.50 per share, before deducting underwriting discounts and commissions and other estimated offering expenses.
Drug Research > Drug Discovery & Development > News
Peloton Therapeutics completes $52.4m Series D financing round
Peloton Therapeutics, a drug discovery and development firm focused on advancing small molecule cancer therapies, has completed a $52.4m Series D financing round.
Drug Research > Drug Discovery & Development > News
Allergan to buy Vitae Pharmaceuticals for $639m
By PBR Staff Writer
Allergan has agreed to acquire US-based clinical-stage biotechnology firm Vitae Pharmaceuticals for about $639m.
Drug Research > Drug Discovery & Development > News
Diabetes startup AnTolRx secures funding from Pfizer, JDRF and Orion Equity
AnTolRx has signed a Series A funding agreement with Pfizer, Orion Equity Partners and JDRF, a global organization funding type 1 diabetes (T1D) research.
Drug Research > Drug Discovery & Development > News
Horizon Discovery, Fulcrum partner for novel CRISPR-based target discovery in genetic diseases
By PBR Staff Writer
UK-based Horizon Discovery Group has partnered with US biotechnology firm Fulcrum Therapeutics for novel CRISPR-based target discovery in genetic diseases.
Drug Research > Drug Discovery & Development > News
Merck discontinues osteoporosis drug development on increased risk of stroke
By PBR Staff Writer
Merck said it would stop the development of its experimental osteoporosis drug, odanacatib, because it carries a higher risk of stroke.
Drug Research > Drug Discovery & Development > News
Taiho Ventures invests in Arcus Biosciences
Taiho Ventures has invested in California-based immuno-oncology firm Arcus Biosciences.
Drug Research > Drug Discovery & Development > News
Takeda gets financial support from US to develop Zika vaccine
By PBR Staff Writer
Japanese drugmaker Takeda Pharmaceutical has won US government funding to develop a vaccine for the mosquito-borne Zika virus.
Drug Research > Drug Discovery & Development > News
Singapore sees first case of pregnant woman with Zika virus
By PBR Staff Writer
Singapore has confirmed its first case of a pregnant woman testing positive for the Zika virus infection, as the number of cases of mosquito-borne virus reached 115 in the country.
Drug Research > Drug Discovery & Development > News
BioLineRx and I-Bridge Capital establish drug development JV in China
BioLineRx has established a joint venture (JV) with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China.
Drug Research > Drug Discovery & Development > News
F-star, Denali Therapeutics partner to develop multispecific antibody platform
By PBR Staff Writer
UK-based biopharmaceutical firm F-star has signed a collaborative agreement with the US start-up Denali Therapeutics to develop a multispecific antibody platform for delivering therapeutics across the blood-brain barrier into the central nervous system (CNS).
Drug Research > Drug Discovery & Development > News
Pfizer to acquire Medivation for $14bn
By PBR Staff Writer
Pfizer has agreed to acquire US biopharmaceutical firm Medivation in a transaction valued at about $14bn.
Drug Research > Drug Discovery & Development > News
91-105 of 4361 results